U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C25H27ClN2
Molecular Weight 390.948
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MECLIZINE

SMILES

CC1=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=CC=C1

InChI

InChIKey=OCJYIGYOJCODJL-UHFFFAOYSA-N
InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3

HIDE SMILES / InChI

Molecular Formula C25H27ClN2
Molecular Weight 390.948
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/meclizine.html

Meclizine, a piperazine-derivative H1-receptor antagonist similar to buclizine, cyclizine, and hydroxyzine, is used as an antivertigo/antiemetic agent. Meclizine is used in the management of nausea, vomiting, and dizziness associated with motion sickness and vertigo in diseases affecting the vestibular apparatus. Along with its actions as an antagonist at H1-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone. It is sold under the brand names Bonine, Bonamine, Antivert, Postafen, Sea Legs, and Dramamine II.

CNS Activity

Curator's Comment: central nervous system depressant

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q922E4
Gene ID: 68671.0
Gene Symbol: Pcyt2
Target Organism: Mus musculus (Mouse)
31.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ANTIVERT

Approved Use

Effective: Management of nausea and vomiting, and dizziness associated with motion sickness. Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system.

Launch Date

2012
Primary
ANTIVERT

Approved Use

Effective: Management of nausea and vomiting, and dizziness associated with motion sickness. Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system.

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
99.43 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
99.43 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
130 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
223 ng/mL
25 mg 2 times / day multiple, oral
dose: 25 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
149 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
131.3 ng/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
210.8 ng/mL
25 mg 2 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
564.03 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
564.03 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
671 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
2030 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
656 ng × h/mL
25 mg 1 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
1891 ng × h/mL
25 mg 2 times / day steady-state, oral
dose: 25 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.24 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.24 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.5 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FASTED
3.6 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
50 mg single, oral
Recommended
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Other AEs: Drowsiness...
Other AEs:
Drowsiness (30%)
Sources:
25 mg 2 times / day multiple, oral
Recommended
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, 5-10
Health Status: unhealthy
Age Group: 5-10
Sex: M+F
Sources:
25 mg single, oral
Recommended
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
unhealthy, 6-10
Health Status: unhealthy
Age Group: 6-10
Sex: M+F
Sources:
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy
Other AEs: Drowsiness...
AEs

AEs

AESignificanceDosePopulation
Drowsiness 30%
50 mg single, oral
Recommended
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
Drowsiness
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Drug-induced extrapyramidal signs in chronic liver disease--a case report.
1977
Pentoxifylline-induced musical hallucinations.
1993 Aug
Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy.
2003 Oct
Patents

Patents

Sample Use Guides

Usual Adult Dose for Vertigo -25 to 100 mg orally per day in divided doses Usual Adult Dose for Motion Sickness -Initial Dose: 25 to 50 mg orally 1 hour before travel -Maintenance Dose: Repeat dose every 24 hours if needed
Route of Administration: Oral
50 uM meclizine inhibited respiratory growth of human skin fibroblasts
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:43:35 GMT 2025
Edited
by admin
on Mon Mar 31 18:43:35 GMT 2025
Record UNII
3L5TQ84570
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MECLOZINE
INN   WHO-DD  
INN  
Preferred Name English
MECLIZINE
HSDB   MI   VANDF  
Common Name English
meclozine [INN]
Common Name English
1-(P-CHLORO-.ALPHA.-PHENYLBENZYL)-4-(M-METHYLBENZYL)PIPERAZINE
Common Name English
MECLIZINE [MI]
Common Name English
NSC-169189
Code English
MECLIZINE [VANDF]
Common Name English
Meclozine [WHO-DD]
Common Name English
MECLIZINE [HSDB]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
WHO-ATC R06AE05
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
WHO-ATC R06AE55
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
WHO-VATC QR06AE55
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
LIVERTOX NBK547895
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
WHO-VATC QR06AE05
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
NDF-RT N0000178372
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
NCI_THESAURUS C267
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
NDF-RT N0000009034
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
NDF-RT N0000009034
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
Code System Code Type Description
RXCUI
6676
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB00737
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
PUBCHEM
4034
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
WIKIPEDIA
MECLOZINE
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
ChEMBL
CHEMBL1623
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
EVMPD
SUB08685MIG
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
NCI_THESAURUS
C61610
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
LACTMED
Meclizine
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
FDA UNII
3L5TQ84570
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
DRUG CENTRAL
1649
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
NSC
169189
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
SMS_ID
100000081967
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
MERCK INDEX
m7118
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY Merck Index
IUPHAR
2757
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
ECHA (EC/EINECS)
209-323-3
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
DAILYMED
3L5TQ84570
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
MESH
D008468
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
HSDB
3113
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
INN
204
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
EPA CompTox
DTXSID0023242
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
CAS
569-65-3
Created by admin on Mon Mar 31 18:43:35 GMT 2025 , Edited by admin on Mon Mar 31 18:43:35 GMT 2025
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
ENANTIOMER -> RACEMATE
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
RECOMBINANT ENZYME
SUBSTRATE
Km
METABOLIC ENZYME -> SUBSTRATE
SUBSTRATE
Vmax
METABOLIC ENZYME -> NON-SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY